Analysts Upgrade Dr Reddy's, Rallis India, Gujarat Gas After Strong Q3 Results

• CLSA upgraded Dr Reddy's Laboratories to 'Hold' with a raised price target of ₹1,210, citing strong growth in emerging markets and India.
• Dr Reddy's US business, excluding Revlimid, is expected to grow at a single-digit pace, with semaglutide identified as a potential new revenue driver.
• HSBC upgraded Rallis India to 'Buy' with a ₹300 price target due to stronger-than-expected Q3FY26 performance and improved earnings visibility.
• Rallis India's business transformation is showing results across all segments, including seeds and exports, beyond domestic crop protection.
• CLSA upgraded Gujarat Gas to 'Hold' with a ₹375 price target, as Q3 profit was in-line and Morbi volumes recovered post-price cut.

Why It Matters: Brokerage firms upgraded Dr Reddy's, Rallis India, and Gujarat Gas following impressive Q3 earnings and positive outlooks.